{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:16:50Z","timestamp":1786119410377,"version":"build-2736575974"},"reference-count":78,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1097\/gco.0b013e328332c910","type":"journal-article","created":{"date-parts":[[2009,11,3]],"date-time":"2009-11-03T03:15:48Z","timestamp":1257218148000},"page":"457-464","source":"Crossref","is-referenced-by-count":21,"title":["Current prophylactic HPV vaccines and gynecologic premalignancies"],"prefix":"10.1097","volume":"21","author":[{"given":"Diane M","family":"Harper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-2-20210129","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.virol.2008.11.046","article-title":"Papillomaviruses in the causation of human cancers: a brief historical account","volume":"384","author":"Zur Hausen","year":"2009","journal-title":"Virology"},{"key":"R3-2-20210129","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1136\/bmj.318.7188.904","article-title":"Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics","volume":"318","author":"Quinn","year":"1999","journal-title":"Br Med J"},{"key":"R5-2-20210129","first-page":"1","article-title":"Prediction of cancer incidence in the Nordic countries up to the years 2000 and 2010. A collaborative study of the five Nordic Cancer Registries","volume":"38","author":"Engeland","year":"1993","journal-title":"APMIS Suppl"},{"key":"R7-2-20210129","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics, 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"Cancer J Clinicians"},{"key":"R8-2-20210129","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/oxfordjournals.jncimonographs.a003479","article-title":"Chapter 1: human papillomavirus and cervical cancer: burden and assessment of causality","volume":"31","author":"Bosch","year":"2003","journal-title":"J Natl Cancer Inst Monogr"},{"key":"R9-2-20210129","first-page":"307","article-title":"New technologies in cervical cytology screening: a word of caution","volume":"94","author":"Sawaya","year":"1999","journal-title":"Obstet Gynecol"},{"key":"R10-2-20210129","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1158\/1055-9965.EPI-07-0278","article-title":"A longitudinal Swedish study on screening for squamous cell carcinoma and adenocarcinoma: evidence of effectiveness and overtreatment","volume":"16","author":"Gunnell","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R11-2-20210129","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1158\/1055-9965.EPI-05-0231","article-title":"Incidence trends of adenocarcinoma of the cervix in 13 European countries","volume":"14","author":"Bray","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R12-2-20210129","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/oxfordjournals.jncimonographs.a003488","article-title":"Chapter 13: primary screening of cervical cancer with human papillomavirus tests","volume":"31","author":"Franco","year":"2003","journal-title":"J Natl Cancer Inst Monogr"},{"key":"R13-2-20210129","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1471-0528.2002.99023.x","article-title":"The psychological impact of abnormal cytology and colposcopy","volume":"109","author":"Rogstad","year":"2002","journal-title":"Br J Obstet Gynaecol"},{"key":"R14-2-20210129","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2303.2009.00669.x","article-title":"The treatment of CIN: what are the risks?","volume":"20","author":"Prendiville","year":"2009","journal-title":"Cytopathology"},{"key":"R16-2-20210129","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1136\/bmj.38663.459039.7C","article-title":"Risk of cervical and other cancers after treatment of CIN","volume":"331","author":"Kalliala","year":"2005","journal-title":"Br Med J"},{"key":"R17-2-20210129","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/jnci\/djp089","article-title":"Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study","volume":"101","author":"Melnikow","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"R18-2-20210129","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1470-2045(07)70043-8","article-title":"Risk of anogenital cancer after diagnosis of cervical intraepithelial neoplasia: a prospective population-based study","volume":"8","author":"Edgren","year":"2007","journal-title":"Lancet Oncol"},{"key":"R19-2-20210129","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000214922","article-title":"Prevention of human papillomavirus infections and associated diseases by vaccination: a new hope for global public health.","volume":"12","author":"Harper","year":"2009","journal-title":"Public Health Genom"},{"key":"R20-2-20210129","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1086\/430274","article-title":"Seroprevalence of human papillomavirus type 16 in children","volume":"191","author":"Dunne","year":"2005","journal-title":"JID"},{"key":"R21-2-20210129","doi-asserted-by":"crossref","first-page":"487.e1","DOI":"10.1016\/j.ajog.2008.12.028","article-title":"Human papillomavirus infection prior to coitarche","volume":"200","author":"Doerfler","year":"2009","journal-title":"Am J Obstet Gynecol"},{"key":"R22-2-20210129","first-page":"45","article-title":"Primary cervical cancer truly negative for high-risk human papillomavirus is a rare but distinct entity that can affect virgins and young adolescents","volume":"30","author":"Liebrich","year":"2009","journal-title":"Eur J Gynaecol Oncol"},{"key":"R23-2-20210129","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1473-3099(07)70158-5","article-title":"Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis","volume":"7","author":"de Sanjos\u00e9","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"R24-2-20210129","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1086\/516784","article-title":"A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion","volume":"195","author":"Plummer","year":"2007","journal-title":"J Infect Dis"},{"key":"R25-2-20210129","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/jnci\/djn044","article-title":"Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections","volume":"100","author":"Rodriguez","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R26-2-20210129","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(08)70103-7","article-title":"Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study","volume":"9","author":"McCredie","year":"2008","journal-title":"Lancet Oncol"},{"key":"R27-2-20210129","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S1470-2045(08)70110-4","article-title":"Heterogeneity in CIN3 diagnosis","volume":"9","author":"Schiffman","year":"2008","journal-title":"Lancet Oncol"},{"key":"R28-2-20210129","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 virus-like particle vaccine among young women with preexisting infection: a randomized trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"J Am Med Assoc"},{"key":"R29-2-20210129","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(09)61248-4","article-title":"Efficacy of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women","volume":"374","author":"Paavonen","year":"2009","journal-title":"Lancet"},{"key":"R30-2-20210129","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1016\/j.vaccine.2008.09.073","article-title":"HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine","volume":"26","author":"Joura","year":"2008","journal-title":"Vaccine"},{"key":"R32-2-20210129","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1086\/597308","article-title":"Human Papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types","volume":"199","author":"Herrero","year":"2009","journal-title":"JID"},{"issue":"3 Suppl 1","key":"R33-2-20210129","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.ygyno.2008.06.027","article-title":"A review of cross-protection against oncogenic HPV by an HPV-16\/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention","volume":"110","author":"Jenkins","year":"2008","journal-title":"Gynecol Oncol"},{"key":"R34-2-20210129","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/jmv.21429","article-title":"Cervical infections by multiple human papillomavirus (HPV) genotypes: prevalence and impact on the risk of precancerous epithelial lesions","volume":"81","author":"Bello","year":"2009","journal-title":"J Med Virol"},{"key":"R36-2-20210129","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16\u201326 years","volume":"199","author":"Brown","year":"2009","journal-title":"J Infect Dis"},{"key":"R38-2-20210129","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/AOG.0b013e31819bd6e0","article-title":"Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors","volume":"113","author":"Smith","year":"2009","journal-title":"Obstet Gynecol"},{"key":"R39-2-20210129","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1086\/597118","article-title":"Comparison of incident cervical and vulvar\/vaginal human papillomavirus infections in newly sexually active young women","volume":"199","author":"Winer","year":"2009","journal-title":"J Infect Dis"},{"key":"R40-2-20210129","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(07)60777-6","article-title":"Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials","volume":"369","author":"Joura","year":"2007","journal-title":"Lancet"},{"key":"R41-2-20210129","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/AOG.0b013e31819b413f","article-title":"Outcome and patterns of recurrence for international federation of gynecology and obstetrics (FIGO) Stages I and II squamous cell vulvar cancer","volume":"113","author":"Tantipalakorn","year":"2009","journal-title":"Obstet Gynecol"},{"key":"R42-2-20210129","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1542\/peds.2006-0461","article-title":"Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women","volume":"118","author":"Block","year":"2006","journal-title":"Pediatrics"},{"key":"R43-2-20210129","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jadohealth.2007.02.015","article-title":"Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant","volume":"40","author":"Pedersen","year":"2007","journal-title":"J Adolesc Health"},{"key":"R44-2-20210129","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/01.inf.0000253970.29190.5a","article-title":"Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial","volume":"26","author":"Reisinger","year":"2007","journal-title":"Pediatric Infect Dis J"},{"key":"R45-2-20210129","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jadohealth.2008.10.002","article-title":"Immunogenicity and safety of human papillomavirus (HPV)-16\/18 AS04-adjuvanted vaccine in healthy boys aged 10\u201318 years","volume":"44","author":"Petaja","year":"2009","journal-title":"J Adolesc Health"},{"key":"R46-2-20210129","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(09)60691-7","article-title":"Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus recombinant vaccine in women aged 24\u201345 years: a randomised, double blind trial","volume":"373","author":"Munoz","year":"2009","journal-title":"Lancet"},{"key":"R47-2-20210129","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.vaccine.2008.10.088","article-title":"Immunogenicity and tolerability of an HPV-16\/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15\u201355 years","volume":"27","author":"Schwarz","year":"2009","journal-title":"Vaccine"},{"key":"R48-2-20210129","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3201\/eid1301.060438","article-title":"Model for assessing human papillomavirus vaccination strategies","volume":"13","author":"Elbasha","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"R50-2-20210129","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"Br J Cancer"},{"key":"R51-2-20210129","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1086\/588140","article-title":"Protecting the next generation: what is the role of the duration of human papillomavirus vaccine-related immunity?","volume":"197","author":"Gunther","year":"2008","journal-title":"J Infect Dis"},{"key":"R52-2-20210129","doi-asserted-by":"crossref","first-page":"4795","DOI":"10.1016\/j.vaccine.2008.07.002","article-title":"Rationale and design of a community-based double blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica","volume":"26","author":"Herrero","year":"2008","journal-title":"Vaccine"},{"key":"R53-2-20210129","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1258\/095646206778145550","article-title":"Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing","volume":"17","author":"Lehtinen","year":"2006","journal-title":"Int J STD AIDS"},{"key":"R55-2-20210129","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1473-3099(09)70108-2","article-title":"Clinician's guide to human papillomavirus immunology: knowns and unknowns","volume":"9","author":"Einstein","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"R56-2-20210129","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4161\/hv.4.6.6912","article-title":"Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16\/18 cervical cancer vaccine","volume":"4","author":"Dessy","year":"2008","journal-title":"Human Vaccines"},{"issue":"29\u201330","key":"R57-2-20210129","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1016\/j.vaccine.2008.04.074","article-title":"Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women","volume":"26","author":"Kemp","year":"2008","journal-title":"Vaccine"},{"key":"R58-2-20210129","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4161\/hv.5.10.9518","article-title":"Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.","volume":"5","author":"Einstein","year":"2009","journal-title":"Human Vaccines"},{"key":"R59-2-20210129","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1016\/j.vaccine.2007.03.049","article-title":"Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6\/11\/16\/18 L1 virus-like particle (VLP) vaccine","volume":"2","author":"Olsson","year":"2007","journal-title":"Vaccine"},{"key":"R60-2-20210129","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","author":"Koutsky","year":"2007","journal-title":"N Engl J Med"},{"key":"R61-2-20210129","first-page":"457","article-title":"Syncope after vaccination: United States, January 2005-July 2007.","volume":"57","year":"2008","journal-title":"Morb Mortal Wkly Rep"},{"key":"R62-2-20210129","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/AOG.0b013e318191a54a","article-title":"Cervical cancers after human papillomavirus vaccination","volume":"113","author":"Beller","year":"2009","journal-title":"Obstet Gynecol"},{"key":"R63-2-20210129","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/DAD.0b013e318185a691","article-title":"Aluminum granuloma after administration of the quadrivalent human papillomavirus vaccine. Report of a case","volume":"30","author":"Marsee","year":"2008","journal-title":"Am J Dermatopathol"},{"key":"R64-2-20210129","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1592\/phco.28.9.1194","article-title":"Development of unilateral cervical and supraclavicular lymphadenopathy after human papillomavirus vaccination","volume":"28","author":"Studdiford","year":"2008","journal-title":"Pharmacotherapy"},{"key":"R65-2-20210129","doi-asserted-by":"crossref","first-page":"a2642","DOI":"10.1136\/bmj.a2642","article-title":"Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study","volume":"337","author":"Kang","year":"2008","journal-title":"Br Med J"},{"key":"R66-2-20210129","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1503\/cmaj.080916","article-title":"Anaphylaxis following quadrivalent human papillomavirus vaccination","volume":"179","author":"Brotherton","year":"2008","journal-title":"Can Med Assoc J"},{"key":"R67-2-20210129","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1016\/j.vaccine.2008.06.074","article-title":"Brachial plexus neuritis following HPV vaccination","volume":"26","author":"Debeer","year":"2008","journal-title":"Vaccine"},{"key":"R68-2-20210129","doi-asserted-by":"crossref","first-page":"178","DOI":"10.5694\/j.1326-5377.2008.tb01960.x","article-title":"Pancreatitis following human papillomavirus vaccination","volume":"189","author":"Das","year":"2008","journal-title":"Med J Australia"},{"key":"R69-2-20210129","first-page":"6","article-title":"Two unclear cases of death. Can we still recommend HPV vaccination?","volume":"150","author":"Lower","year":"2008","journal-title":"MMW Fortschritte der Medizin"},{"key":"R70-2-20210129","first-page":"371","article-title":"Annual report: surveillance of adverse events following immunisation in Australia, 2007","volume":"32","author":"Lawrence","year":"2008","journal-title":"Commun Dis Intell"},{"key":"R71-2-20210129","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1212\/WNL.0b013e3181aa53bb","article-title":"Acute disseminated encephalomyelitis following vaccination against human papillomavirus","volume":"72","author":"Wildemann","year":"2009","journal-title":"Neurology"},{"key":"R73-2-20210129","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/INF.0b013e3181a6a511","article-title":"Adversomics: the emerging field of vaccine adverse event immunogenetics","volume":"28","author":"Poland","year":"2009","journal-title":"Pediatric Infect Dis J"},{"key":"R74-2-20210129","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/1352458508096868","article-title":"CNS demyelination and quadrivalent HPV vaccination","volume":"15","author":"Sutton","year":"2009","journal-title":"Multiple Sclerosis"},{"key":"R75-2-20210129","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/jama.2009.1201","article-title":"Postlicensure safety surveillance for quadrivalent HPV recombinant vaccine","volume":"302","author":"Slade","year":"2009","journal-title":"J Am Med Assoc"},{"key":"R76-2-20210129","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1258\/jms.2008.008011","article-title":"Sociodemographic predictors of HPV testing and vaccination acceptability: results from a population-representative sample of British women","volume":"15","author":"Marlow","year":"2008","journal-title":"J Med Screening"},{"issue":"4 Suppl","key":"R77-2-20210129","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/j.jadohealth.2008.06.015","article-title":"Potential barriers to HPV vaccine provision among medical practices in an area with high rates of cervical cancer","volume":"43","author":"Keating","year":"2008","journal-title":"J Adolesc Health"},{"key":"R78-2-20210129","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/bmj.39541.534109.BE","article-title":"Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study","volume":"336","author":"Brabin","year":"2008","journal-title":"Br Med J"},{"key":"R79-2-20210129","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.jadohealth.2008.09.011","article-title":"Mothers' and adolescents' beliefs about risk compensation following HPV vaccination","volume":"44","author":"Marlow","year":"2009","journal-title":"J Adolesc Health"},{"key":"R80-2-20210129","first-page":"72","article-title":"HPV vaccination catch up program: utilisation by young Australian women","volume":"38","author":"Weisberg","year":"2009","journal-title":"Australian Family Physician"},{"key":"R82-2-20210129","doi-asserted-by":"crossref","first-page":"e138","DOI":"10.1371\/journal.pmed.0030138","article-title":"Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses","volume":"3","author":"Barnabas","year":"2006","journal-title":"PLoS Med"},{"key":"R83-2-20210129","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.1016\/j.vaccine.2008.04.053","article-title":"Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries","volume":"26","author":"Goldie","year":"2008","journal-title":"Vaccine"},{"key":"R84-2-20210129","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMsa0707052","article-title":"Health and economic implications of HPV vaccination in the United States","volume":"359","author":"Kim","year":"2008","journal-title":"N Engl J Med"},{"key":"R85-2-20210129","doi-asserted-by":"crossref","first-page":"a769","DOI":"10.1136\/bmj.a769","article-title":"Economic evaluation of human papillomavirus vaccination in the United Kingdom","volume":"337","author":"Jit","year":"2008","journal-title":"Br Med J"},{"key":"R86-2-20210129","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/sj.bjc.6604462","article-title":"Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India","volume":"99","author":"Diaz","year":"2008","journal-title":"Br J Cancer"},{"key":"R87-2-20210129","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/jnci\/djn019","article-title":"Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16, 18 vaccination","volume":"100","author":"Goldhaber-Fiebert","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R88-2-20210129","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3201\/eid1402.070499","article-title":"Cost-effectiveness of human papillomavirus vaccination in the United States","volume":"14","author":"Chesson","year":"2008","journal-title":"Emerg Infect Dis"},{"issue":"10 Suppl","key":"R90-2-20210129","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1002\/cncr.23762","article-title":"Predicting the effect of successful human papillomavirus vaccination on existing cervical cancer prevention programs in the United States","volume":"113","author":"Castle","year":"2008","journal-title":"Cancer"}],"container-title":["Current Opinion in Obstetrics & Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/GCO.0b013e328332c910","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:05:41Z","timestamp":1786039541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001703-200912000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/gco.0b013e328332c910","relation":{},"ISSN":["1040-872X"],"issn-type":[{"value":"1040-872X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}